Loading clinical trials...

A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia | Clinical Trials | Clareo Health

COMPLETEDPhase 3NCT01833494

A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

The purpose of this study is to investigate the safety and efficacy for 52-week dosing in hemodialysis patients with hyperphosphatemia.

Lead sponsor: Kissei Pharmaceutical Co., Ltd.•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Trial snapshot

StatusCOMPLETED

PhasePHASE3

Enrollment161

Start dateMar 2013

Last updatedOct 9, 2018

Condition

Hemodialysis Patients With Hyperphosphatemia

Locations shown

JAPAN

Multiple Locations

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 9, 2018Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions